<SEC-DOCUMENT>0001193125-25-274282.txt : 20251110
<SEC-HEADER>0001193125-25-274282.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110161538
ACCESSION NUMBER:		0001193125-25-274282
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20251110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39926
		FILM NUMBER:		251466415

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tern-20251110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-10T15:20:46.1220+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:tern="http://www.ternspharma.com/20251110" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_695e3b41-b754-47bd-b5f7-7fa73cc808bd" name="dei:EntityCentralIndexKey" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7">0001831363</ix:nonNumeric><ix:nonNumeric id="F_e86f0776-141a-489c-8afc-5bda5fe5008e" name="dei:AmendmentFlag" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tern-20251110.xsd"/></ix:references><ix:resources><xbrli:context id="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-10</xbrli:startDate><xbrli:endDate>2025-11-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_979c1d9d-cf7d-48eb-aadf-d86e3441fa25" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_3d8fcb1c-f66e-44fa-bd47-7d2dd3464ac6" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">November 10, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_769ea3c0-5e8e-478d-9535-ae6f643f2ff7" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terns Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_27c45070-6ec2-494d-90b3-6d79519d5234" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_faed0e80-e264-4d8d-986f-64b49aa7e705" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-39926</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_50f6bb40-552c-45cb-9ad4-4a6ef1ef5847" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">98-1448275</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_548871f4-94dd-44b3-87cb-2c5b03feef12" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1065 East Hillsdale Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_de48ac85-ca2c-4aa8-9ac4-c1b4a4dd2ce7" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5c3e88d2-9062-461c-86f2-5affd36e77c0" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foster City</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_14949f1f-9ba2-4589-b244-cf4ebaad4bec" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5a06b4df-a69c-4654-9dd5-a7c1988c4eb0" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94404</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_42966926-614e-4f82-9111-17412d1aff56" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_6bd25661-ba6c-4e87-a868-23ad85144593" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">525-5535</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_63499fdf-3786-4bfe-a91e-77105f18e5c2" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_345660c4-da25-4772-a08c-470f992910b2" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b8c3c61-a756-407e-b770-1c5c93470601" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f5fc9c4-0407-4c53-bbb5-e3c45a9950b7" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38a8f7a3-0007-4988-9497-31699b438cf9" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1px solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.011pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1px solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.011pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1px solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_512a4f45-bd68-4e50-ac1d-da2e83370763" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_339e66ac-b7bf-4274-bd65-6ec2b2d1f899" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TERN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2c9df292-98b4-44d3-baf2-b9073dc3c620" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_39f8b705-a665-467b-a3f6-bc2af816053d" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_df36280a-6e43-4da1-87fb-6e13acc6e7a5" contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 	Results of Operations and Financial Condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 10, 2025, Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01	Financial Statements and Exhibits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:7.5%;box-sizing:content-box;"/>
     <td style="width:2.5%;box-sizing:content-box;"/>
     <td style="width:90%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tern-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by Terns Pharmaceuticals, Inc. on November 10, 2025.</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:52.14%;box-sizing:content-box;"/>
     <td style="width:3.24%;box-sizing:content-box;"/>
     <td style="width:44.62%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: November 10, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andrew Gengos</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrew Gengos</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-11-10T15:20:46.2070+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.3in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img52906712_0.jpg" alt="img52906712_0.jpg" style="width:160px;height:45px;"></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">FOSTER CITY, Calif., November 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (&#x201c;Terns&#x201d; or the &#x201c;Company&#x201d;) (Nasdaq: TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We&#x2019;re thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1 MMR achievement rate and encouraging safety/tolerability profile published in the recent ASH abstract. These data continue to reinforce our view of the potential of TERN-701 to become a best-in-disease treatment for patients with chronic myeloid leukemia (CML),&#x201d; said Amy Burroughs, chief executive officer of Terns Pharmaceuticals. &#x201c;Our team continues to execute with precision and focus towards an updated and expanded CARDINAL readout at ASH, with an ultimate goal of bringing this important new therapy to CML patients.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Recent Pipeline Developments and Anticipated Milestones</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">TERN-701: Novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In November 2025, Terns announced that an </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">abstract</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> with updated data from the ongoing Phase 1 CARDINAL trial evaluating TERN-701 in patients with relapsed/refractory CML had been selected for oral presentation at the 67th ASH Annual Meeting and Exposition</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The abstract reported data from the ongoing dose escalation and dose expansion parts of the CARDINAL trial. Highlights include from the abstract include:</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Overall (cumulative) major molecular response (MMR) rate of 75% by 24 weeks, with 64% achieving MMR and 100% maintaining MMR</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Overall (cumulative) MMR by 24 weeks in difficult to treat patient subgroups</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.999615998463994%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">69% in patients with lack of efficacy to last tyrosine kinase inhibitor (TKI) </font></div></div><div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.999615998463994%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">60% in patients who had prior asciminib</font></div></div><div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.999615998463994%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">67% in patients with prior asciminib / ponatinib / investigational TKI </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">No patients had lost MMR at the time of data cutoff</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Encouraging safety and tolerability profile at all doses evaluated</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">A more expansive and updated dataset from the CARDINAL trial will be presented at the ASH Annual Meeting:</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Session Name: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Therapeutic agents to enhance patient outcomes</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Session Date: December 8, 2025</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Session Time: 2:45 &#x2013; 4:15pm ET</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Presentation Time: 2:45 &#x2013; 3:00pm ET</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company will host a conference call to review the data on December 8, 2025 at 4:30pm ET. The event can be accessed live on the investor relations </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">section</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> of Terns&#x2019; website, where it will also be archived</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.3in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">TERN-601: Oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) for obesity</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In October 2025, Terns announced top-line 12-week data from the Phase 2 study of TERN-601 for the treatment of obesity, which showed maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The results of the Phase 2 study did not support the Company&#x2019;s further development of TERN-601 in obesity</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Terns had previously announced its decision to no longer invest in metabolic disease </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Pipeline and Partnering Programs</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;As we continue to sharpen our strategic focus in oncology, earlier this year we decided we would discontinue internal clinical development of our metabolic programs. While these metabolic assets have shown promise, we believe their full potential can best be realized through external partnerships,&#34; noted Andrew Gengos, chief financial officer of Terns.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">TERN-501: Oral, thyroid hormone receptor-beta (THR-&#x3b2;) agonist</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Based on non-clinical studies, THR-&#x3b2; is a complementary mechanism to GLP-1, potentially providing broader metabolic and liver benefits in addition to increased weight loss</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Terns is seeking a strategic partner to advance this program</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">TERN-801: Oral, small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In the third quarter of 2025, Terns nominated TERN-801, an oral small-molecule GIPR antagonist as a development candidate from the TERN-800 series discovery effort</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Terns is seeking a strategic partner to advance this program</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Third Quarter 2025 Financial Results</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash Position:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> As of September 30, 2025, cash, cash equivalents and marketable securities were $295.6 million, as compared with $358.2 million as of December 31, 2024. Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2028.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and Development (R&amp;D) Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">R&amp;D expenses were $19.9 million for the quarter ended September 30, 2025, as compared with $15.2 million for the quarter ended September 30, 2024.	</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and Administrative (G&amp;A) Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> G&amp;A expenses were $7.8 million for the quarter ended September 30, 2025, as compared with $9.8 million for the quarter ended September 30, 2024.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net Loss:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Net loss was $24.6 million for the quarter ended September 30, 2025, as compared with $21.9 million for the quarter ended September 30, 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.3in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Tables</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terns Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations</font></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited; in thousands except share and per share amounts)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50.38%;box-sizing:content-box;"></td>
     <td style="width:1.22%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.22%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.22%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.22%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended September 30,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nine Months Ended September 30,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,917</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,169</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,990</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,108</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,799</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,770</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,536</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,814</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,716</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,939</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,526</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,922</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(27,716</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,939</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(82,526</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(75,922</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,141</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,088</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,134</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,146</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(46</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(58</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,589</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,883</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(72,438</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(66,834</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(46</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(62</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(198</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(220</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,635</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,945</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(72,636</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,054</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.27</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.28</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.79</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.89</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common stock outstanding, basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,701,529</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,819,658</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,584,339</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,567,851</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terns Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selected Balance Sheet Data</font></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited; in thousands)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:53.049%;box-sizing:content-box;"></td>
     <td style="width:1.8%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:19.676%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.8%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:19.676%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30, 2025</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295,635</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358,164</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">301,651</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,929</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,585</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,059</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">284,066</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,870</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Terns Pharmaceuticals</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more information, please visit: </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.ternspharma.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.3in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements about the Company within the meaning of the federal securities laws that involve substantial risks and uncertainties. Forward-looking statements include statements related to or in connection with expectations, timing and potential results of clinical trials and other development activities, including with respect to the CARDINAL trial; the potential indications to be targeted by the Company with its product candidates; the therapeutic potential of the Company&#x2019;s product candidates; the potential for the mechanisms of action of the Company&#x2019;s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company&#x2019;s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company&#x2019;s clinical trials; the applicability of expected parameters and benchmarks on which to assess clinical trial results; the Company&#x2019;s clinical development plans and activities, including potential future trial designs, milestones and results of any interactions with regulatory authorities on its programs; the Company&#x2019;s expectations regarding the profile and potential beneficial characteristics and therapeutic effects of its product candidates, including with respect to efficacy, tolerability, safety, convenience and pharmacokinetic profile; the potential differentiation of the Company&#x2019;s product candidates compared to similar, competitive or other products or product candidates; the best-in-disease potential of TERN-701; the Company&#x2019;s plans for and ability to continue to execute on its current development strategy; the process, timing or potential to establish a strategic partnership or similar arrangement for future development and/or potential commercialization of any of its product candidates; the potential commercialization of the Company&#x2019;s product candidates; and the Company&#x2019;s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company&#x2019;s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected industry and market trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;develop,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#x2019;s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company&#x2019;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company&#x2019;s actual results, please refer to the risk factors identified in the Company&#x2019;s reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. New risk factors emerge from time to time and it is not possible for Company management to predict all risk factors, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.3in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Contacts for Terns</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investors</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Justin Ng</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">investors@ternspharma.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Media</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Jenna Urban</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CG Life</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">media@ternspharma.com</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img52906712_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img52906712_0.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "( >$# 2(  A$! Q$!_\0
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M,+FV7X+,\-"O&,*\</C\-2Q5&-:$)U(1JQIU8JI&%2I&,TU&<TE)_CF,PM3
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M*5%8?AC4Y];\->'M9N4BBN=7T/2=3N(H XACGO["WNY4A$C.XB225EC#N[A
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MH-CKKW'B+1=$:TN-7M;'4KBQ1(]5>X66*QN"SP+$557+K_'J/^#R/XL$@?\
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MZO.,IT)SY*N&Q5.+2E4PF+H2J8;$1BW%3]E5E*DY*-6,)OE/I\NS3 9K1=?
M8F%>$6E-+FC4IR:NHU:4U&I3;Z<T4I6;BVM26BBBOFST HHK\;_^"I?_  6O
M_99_X)?Z,GASQ9)<_%K]HK7-(&J^$_@)X-U*TMM7BL;C<MAX@^(>ORQ7MKX
M\,7<B-]CN+JQU+7]95))-"\/:E:07MY9>KDN1YMQ%F-#*<DP&(S',,2VJ6&P
M\4Y<L=9U*DY.-*A1II\U6O6G3HTH^]4G&.IS8O&87 T)XG&5X8>A3^*I4=E=
M[1BDG*<Y;1A!2G)Z1BV?LA17^6Q^U/\ \')7_!47]H_5]13PK\7[;]FCP-/-
M/_9_@WX"Z7;^'=0M;5FQ!]M^(NIKJOQ"O+](@JSW.G^(-%L)9=\UOI%F&$2_
ME[JO[>7[<6N7\FJ:Q^V1^U/J6H2R&5[R\_: ^*\\^]CDLKOXL)CY)PL>U1V
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M_P"9^O\ GP_XEV\;?^C<<0?^ 8/R_P"HOS_!]C_3W_B)? ?_ $4^7??7\O\
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M(0BEK*<Y*,8I:MI)'T\I0IPE*3484XN4I-V4815VVWLDE=M]$?@E_P %_/\
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M_H4T7_@D]_P3+T#2ET73OV"OV4#8K$(2=1^!_@'6KZ5 H7,^JZUHNH:K<RD
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M6+X<K_1?_P"#I[_E$UXO_P"RX_!?_P!/&IU_G0?LE_\ )U/[,_\ V<!\&_\
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M/"I"'+3I*:C#WHR;O*I)NSMMI='^R[17^-%_P\ _;S_Z/7_:W_\ $C?C%_\
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MPWCDHXW&12LEBL0DELDJTTE\D?L%!WHT6]W2IM_^ (_$/_@X-_8G\5_MN_\
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MXBABJ,*^&K4Z]&HKPJTIJ<)+9VE%M73NI)ZQDG&23304445PFP4444 %%%%
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M@K[MVO)WE)N3;/P6O6K8FK.OB*LZU:HW*=6K)SG)OJY2;;Z6UTLDM$C]<_\
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MQ#^Q=_T:'^R__P"&!^%'_P R=?4%%']L9M_T-,Q_\+<3_P#+0^JX;_H'H?\
M@FG_ /(GR_\ \,0_L7?]&A_LO_\ A@?A1_\ ,G70>%?V3?V6/ OB#2_%O@G]
MFC]G_P '>*M#N#=Z+XF\*_!KX=>'O$&CW9CDA-UI>M:1X<L]2T^X,,LL1FM+
MF&0QR21[MKL#^.G_  7P_P""P>O?\$P_AE\)?#OP-D\%:W^TQ\5?%MMK=AX:
M\8Z?-KVBZ-\(O#$LI\4Z[X@TFPU+2]0BB\3:P+#PEX?D2^L)KK_BJ+W3;Q;O
MP[+M^8_^"97_  <[?#W]M+XM_##]F;XR?LW>-_AU\<OBAKEKX5\+ZW\*;F/X
M@_#;6-9EBDN+B]U73]2DTGQAX'T>TLK>\U*_G*>-K/2--LKN_P!4U>"SMYKA
M/OL+P+XD9GPF^+L)3S'&9%.&-E5:S.7UA8/!\T,3BY8.M7A4K8.\*T.>C&L[
M4:TIPC349R\6IG.0X?,_[+J2H4L;%TE&^'7(ZM6SITE5A!QC5M*#M-P^**BW
M*Z7]4]%%%?F!]"?Y3_\ P<8_\IC_ -L/_K^^#W_J@_A=7[$_\&;O_)8OVY/^
MR:?!C_U*?'-?CM_P<8_\IC_VP_\ K^^#W_J@_A=7[$_\&;O_ "6+]N3_ +)I
M\&/_ %*?'-?WOQC_ ,HY4?\ LBN"_P#TO(#\7RS_ )+R?_8VS3\L8?WKT445
M_!!^T!1110!^2/\ P7>_Y1&?MQ_]DIT[_P!3WP?7^2LO4?4?SK_6I_X+O?\
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MA_!/3-5MGMM1N'U. RV.L_$75+":;3;W4=-DFTGP[IMQ?Z;I-[JDNH7.H1_
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M-;[[=XJ\$W#"&S2:XUSPM!';IH>FG4/S,_X)6_\ !4CXT?\ !+CX]_\ "R_
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M9N_\EB_;D_[)I\&/_4I\<U^.W_!QC_RF/_;#_P"O[X/?^J#^%U?L3_P9N_\
M)8OVY/\ LFGP8_\ 4I\<U_>_&/\ RCE1_P"R*X+_ /2\@/Q?+/\ DO)_]C;-
M/RQA_>O1117\$'[0%%%% 'Y(_P#!=[_E$9^W'_V2G3O_ %/?!]?Y*R]1]1_.
MO]:G_@N]_P HC/VX_P#LE.G?^I[X/K_)67J/J/YU_<GT7O\ DC<\_P"RHJ_^
MJK*C\?\ $3_D:X+_ +%\?_4G$'^S9^PE_P F/_L;?]FJ?L\_^JB\(5]5U\J?
ML)?\F/\ [&W_ &:I^SS_ .JB\(5]5U_%F<?\C;-/^QCC?_4FJ?K&$_W3"_\
M8/1_]-Q"BBBO..@_%/\ X.)/^4.7[97_ &!_A)_ZOOX65_E*+U'U'\Z_U:_^
M#B3_ )0Y?ME?]@?X2?\ J^_A97^4HO4?4?SK^[/HO_\ )#9K_P!E=C/_ %4Y
M&?C?B'_R.<-_V+:/_J3BS_:I_9F_Y-O_ &?O^R(_"C_U ]!KVZO$?V9O^3;_
M -G[_LB/PH_]0/0:]NK^'L?_ +]C?^PO$_\ IZ9^OT/X%'_KU3_](B?R[_\
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M>6LD>C^(O&EA9RO<^%/A]I=R\>H:MK.JBR?5[:VFTKPXNH:O-'#'_G ^,_\
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M&>37<T5EF&>YYFZ2S7.<US-1=XK,,QQ>-2?=+$UJMGYHJA@L'A?]VPF&P_\
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M+FPN!P>&EMS8?#4:,K=KTX1?XA1117B'8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>tern-20251110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-10T15:20:46.4916+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ternspharma.com/20251110" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:tern="http://www.ternspharma.com/20251110" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tern-20251110.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Terns Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1065 East Hillsdale Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">525-5535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TERN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tern-20251110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tern-20251110.htm">tern-20251110.htm</File>
    <File>tern-20251110.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tern-20251110.htm": {
   "nsprefix": "tern",
   "nsuri": "http://www.ternspharma.com/20251110",
   "dts": {
    "inline": {
     "local": [
      "tern-20251110.htm"
     ]
    },
    "schema": {
     "local": [
      "tern-20251110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tern-20251110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tern-20251110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ternspharma.com/20251110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-25-274282-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-274282-xbrl.zip
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MP#R>@ /Z;FFJ5N,QI'PZ[ X[$PJ:E5CX7*Z5"XYHBOHC[@DO,4-!A+I9BMH
M8YC.NS4]&,_5_&L.NZ\<=G?U<^UQ]7R%4O^".B_KR'Y!)?+X\+9E<0#\!0Z\
M/] /]M7Z>)")KQ;*FN410[$4;')/P\0A()055\<FLQQ#=9BAZ:0:H0QR+4[
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M2<$SY=A^HDO@2* 'J*82RPY%A:*;Q<)%;^^.'AQ;,$MR#@]@423<APF*0UX
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M^S2:^%P%.76<BJ0H(XQP^"3^$(2I]F.<]4Y@M<M\KEP19WR,G\XDKJ=*[HW
MZ5P%&.B_$N5_D3D6W'UKOAF+8TN^,082('6R39L?VU:NL$X%!A(@=9)5NB%;
MLH[]WQ , 5KPI\(F^ O'9%?: J-.KH7NR9;$(XL]0OH@/R"!B>YH*UKZ=6AY
M?&:-:4G<ES=2$HQEQI& ;$Q%QI=Y(R$A)@+0VF>E,LOFC=0$J*)=)&[]>G*V
MSFY"(C 4H"& JY^_TNO9386$1"$FBD ;T++F!.TH9(42P.@!6+^*Q"S:C;W
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M$2H9L%!DYR*2G#T#%^NY5VJUX7#S)%JRGS.M53:; PN@<*9@;\ 86<DK=,A
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M87(&U A/E X1^%SKG@YF;A,C@A=:3%$.2B^M79]S< 2%B"&H#EW@C.RYF>.
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M45JC[-7=Y7.J<+H4<S#PFQU:.Q/R*84?[@-]:LH^N-P)/$  O*V G_T:\RR
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M<FP.IN?B $K@V,PO.C=-]@9$J2*!DD>F6:H,!YO) +$R7=[DJ:&W(#0H@<N
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M+3(P,C4Q,3$P+FAT;5!+ 0(4 Q0    ( /&!:ENJ^6T  0D  &9I   1
M          "  9D4  !T97)N+3(P,C4Q,3$P+GAS9%!+ 0(4 Q0    ( /&!
M:ELBLHD& 2(  (-- @ /              "  <D=  !T97)N+65X.3E?,2YH
8=&U02P4&      ,  P"[    ]S\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tern-20251110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tern-20251110.xsd" xlink:type="simple"/>
    <context id="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831363</identifier>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_695e3b41-b754-47bd-b5f7-7fa73cc808bd">0001831363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_e86f0776-141a-489c-8afc-5bda5fe5008e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_979c1d9d-cf7d-48eb-aadf-d86e3441fa25">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_3d8fcb1c-f66e-44fa-bd47-7d2dd3464ac6">2025-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_769ea3c0-5e8e-478d-9535-ae6f643f2ff7">Terns Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_27c45070-6ec2-494d-90b3-6d79519d5234">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_faed0e80-e264-4d8d-986f-64b49aa7e705">001-39926</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_50f6bb40-552c-45cb-9ad4-4a6ef1ef5847">98-1448275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_548871f4-94dd-44b3-87cb-2c5b03feef12">1065 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_de48ac85-ca2c-4aa8-9ac4-c1b4a4dd2ce7">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_5c3e88d2-9062-461c-86f2-5affd36e77c0">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_14949f1f-9ba2-4589-b244-cf4ebaad4bec">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_5a06b4df-a69c-4654-9dd5-a7c1988c4eb0">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_42966926-614e-4f82-9111-17412d1aff56">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_6bd25661-ba6c-4e87-a868-23ad85144593">525-5535</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_63499fdf-3786-4bfe-a91e-77105f18e5c2">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_345660c4-da25-4772-a08c-470f992910b2">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_5b8c3c61-a756-407e-b770-1c5c93470601">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_4f5fc9c4-0407-4c53-bbb5-e3c45a9950b7">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_38a8f7a3-0007-4988-9497-31699b438cf9">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_512a4f45-bd68-4e50-ac1d-da2e83370763">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_339e66ac-b7bf-4274-bd65-6ec2b2d1f899">TERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_2c9df292-98b4-44d3-baf2-b9073dc3c620">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_39f8b705-a665-467b-a3f6-bc2af816053d">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_98b1ce36-95e3-4b20-b939-ac3b443a4ce7"
      id="F_df36280a-6e43-4da1-87fb-6e13acc6e7a5">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
